Last €64.00 EUR
Change Today +5.42 / 9.25%
Volume 849.0
BM8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:41 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Open
€59.13
Previous Close
€58.58
Day High
€64.00
Day Low
€58.39
52 Week High
10/24/14 - €64.00
52 Week Low
05/21/14 - €40.56
Market Cap
9.4B
Average Volume 10 Days
105.5
EPS TTM
--
Shares Outstanding
147.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BM8)

biomarin pharmaceutical inc (BM8) Related Businessweek News

View More BusinessWeek News

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.

1,341 Employees
Last Reported Date: 02/26/14
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $868.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $457.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $631.9K
Senior Vice President, Secretary and General ...
Total Annual Compensation: $409.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $332.6K
Compensation as of Fiscal Year 2013.

biomarin pharmaceutical inc (BM8) Key Developments

BioMarin Pharmaceutical Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year of 2014. for the Year Ending December 31, 2014

BioMarin Pharmaceutical Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $176,847,000 against $136,874,000 a year ago. Income from operations was $11,203,000 against loss from operations of $50,724,000 a year ago. Income before income taxes was $3,221,000 against loss before income taxes of $52,316,000 a year ago. Net income was $7,445,000 against net loss of $53,020,000 a year ago. Basic and diluted earnings per share were $0.05 against basic and diluted loss per share of $0.38 a year ago. Non-GAAP net loss was $22.9 million against $16.7 million for the same period in the last year. Non-GAAP net loss per basic and diluted share was $0.05 against $0.38 for the same period in the last year. EBITDA was $22.8 million against LBITDA of $43.4 million a year ago. For the nine months, the company reported total revenues of $520,186,000 against $401,612,000 a year ago. Loss from operations was $34,135,000 against $103,697,000 a year ago. Loss before income taxes was $59,131,000 against $117,128,000 a year ago. Net loss was $64,172,000 against $114,363,000 a year ago. Basic and diluted loss per share was $0.44 against $0.84 a year ago. Non-GAAP net loss was $13.5 million against $24.6 million for the same period in the last year. Non-GAAP net loss per basic and diluted share was $0.44 against $0.84 for the same period in the last year. LBITDA was $4.0 million against $88.3 million a year ago. The company revised earnings guidance for the full year of 2014. For the year ending December 31, 2014, the company expects total company revenues to be $700 million to $710 million against $680 million to $700 million previously announced guidance. GAAP net loss expected to be $160.0 million to $175.0 million, Non-GAAP loss is expected to be $50.0 million to $65.0 million compared with GAAP net loss of $180 million to $195 million, non-GAAP loss of $60 million to $80 million previously announced guidance. EBITDA expected to be $71.9 million to $86.9 million.

BioMarin Pharmaceutical Inc., Q3 2014 Earnings Call, Oct 23, 2014

BioMarin Pharmaceutical Inc., Q3 2014 Earnings Call, Oct 23, 2014

FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets

BioMarin Pharmaceutical Inc. announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug Administration (FDA) in connection with an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of KUVAN(R) (sapropterin dihydrochloride) Tablets, although it has not yet received notice of the certification. BioMarin has 8 patents listed in the FDA Orange Book with expiration dates between 2024 and 2026. BioMarin will evaluate the Paragraph IV certification when it receives the Notice Letter and intends to vigorously enforce its intellectual property rights. By statute, if BioMarin initiates a patent infringement lawsuit against the party submitting the letter within 45 days of receiving the notice letter, then the FDA would be automatically precluded from approving the ANDA for 30 months, or until a district court decision finding the patents invalid or not infringed, whichever occurs earlier.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €64.00 EUR +5.42

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.112.10 CHF -0.30
Alkermes PLC $45.91 USD +0.63
Dendreon Corp $1.03 USD -0.01
Jazz Pharmaceuticals PLC $166.46 USD +4.16
Spectrum Pharmaceuticals Inc $7.70 USD -0.11
View Industry Companies
 

Industry Analysis

BM8

Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.9x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.biomarinpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.